276 related articles for article (PubMed ID: 24909983)
1. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn.
Kapur R; Della Valle L; Sonneveld M; Hipgrave Ederveen A; Visser R; Ligthart P; de Haas M; Wuhrer M; van der Schoot CE; Vidarsson G
Br J Haematol; 2014 Sep; 166(6):936-45. PubMed ID: 24909983
[TBL] [Abstract][Full Text] [Related]
2. Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn.
Sonneveld ME; Koelewijn J; de Haas M; Admiraal J; Plomp R; Koeleman CA; Hipgrave Ederveen AL; Ligthart P; Wuhrer M; van der Schoot CE; Vidarsson G
Br J Haematol; 2017 Feb; 176(4):651-660. PubMed ID: 27891581
[TBL] [Abstract][Full Text] [Related]
3. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy.
Kapur R; Kustiawan I; Vestrheim A; Koeleman CA; Visser R; Einarsdottir HK; Porcelijn L; Jackson D; Kumpel B; Deelder AM; Blank D; Skogen B; Killie MK; Michaelsen TE; de Haas M; Rispens T; van der Schoot CE; Wuhrer M; Vidarsson G
Blood; 2014 Jan; 123(4):471-80. PubMed ID: 24243971
[TBL] [Abstract][Full Text] [Related]
4. Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.
Kumpel BM; Saldova R; Koeleman CAM; Abrahams JL; Ederveen AH; Armour KL; Olovnikova NI; Vidarsson G; Kapur R; Rudd PM; Wuhrer M
Sci Rep; 2020 Jan; 10(1):1464. PubMed ID: 32001734
[TBL] [Abstract][Full Text] [Related]
5. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia.
Sonneveld ME; Natunen S; Sainio S; Koeleman CA; Holst S; Dekkers G; Koelewijn J; Partanen J; van der Schoot CE; Wuhrer M; Vidarsson G
Br J Haematol; 2016 Jul; 174(2):310-20. PubMed ID: 27017954
[TBL] [Abstract][Full Text] [Related]
6. Immunological principle of development of red blood cell alloimmunization in pregnancy, hemolytic disease of the fetus and prevention of RhD alloimmunization in RhD negative women.
Roubalová L; Lubušký M
Ceska Gynekol; 2020; 85(6):408-416. PubMed ID: 33711901
[TBL] [Abstract][Full Text] [Related]
7. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn.
Hadley AG
Transpl Immunol; 2002 Aug; 10(2-3):191-8. PubMed ID: 12216949
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the protective effect of maternal FcR-blocking IgG alloantibodies HLA-DR in Rh D-haemolytic disease of the newborn.
Dooren MC; van Kamp IL; Kanhai HH; Gravenhorst JB; von dem Borne AE; Engelfriet CP
Vox Sang; 1993; 65(1):55-8. PubMed ID: 8362515
[TBL] [Abstract][Full Text] [Related]
9. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn.
Hadley AG
Vox Sang; 1998; 74 Suppl 2():375-83. PubMed ID: 9704470
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn.
Brinc D; Lazarus AH
Hematology Am Soc Hematol Educ Program; 2009; ():185-91. PubMed ID: 20008198
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D.
Kapur R; Della Valle L; Verhagen OJ; Hipgrave Ederveen A; Ligthart P; de Haas M; Kumpel B; Wuhrer M; van der Schoot CE; Vidarsson G
Transfusion; 2015 Mar; 55(3):553-62. PubMed ID: 25234110
[TBL] [Abstract][Full Text] [Related]
12. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
[TBL] [Abstract][Full Text] [Related]
13. Cellular surface plasmon resonance-based detection of anti-HPA-1a antibody glycosylation in fetal and neonatal alloimmune thrombocytopenia.
Szittner Z; Bentlage AEH; Temming AR; Schmidt DE; Visser R; Lissenberg-Thunnissen S; Mok JY; van Esch WJE; Sonneveld ME; de Graaf EL; Wuhrer M; Porcelijn L; de Haas M; van der Schoot CE; Vidarsson G
Front Immunol; 2023; 14():1225603. PubMed ID: 37868955
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation.
Hyland CA; O'Brien H; Flower RL; Gardener GJ
Transfus Apher Sci; 2020 Oct; 59(5):102947. PubMed ID: 33115620
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the severity of haemolytic disease of the newborn. Quantitative IgG anti-D subclass determinations explain the correlation with functional assay results.
Garner SF; Gorick BD; Lai WY; Brown D; Taverner J; Hughes-Jones NC; Contreras M; Lubenko A
Vox Sang; 1995; 68(3):169-76. PubMed ID: 7625074
[TBL] [Abstract][Full Text] [Related]
16. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR).
Dooren MC; Kuijpers RW; Joekes EC; Huiskes E; Goldschmeding R; Overbeeke MA; von dem Borne AE; Engelfriet CP; Ouwehand WH
Lancet; 1992 May; 339(8801):1067-70. PubMed ID: 1349101
[TBL] [Abstract][Full Text] [Related]
17. Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies.
Sonneveld ME; Koeleman CAM; Plomp HR; Wuhrer M; van der Schoot CE; Vidarsson G
Front Immunol; 2018; 9():129. PubMed ID: 29445378
[TBL] [Abstract][Full Text] [Related]
18. Severe anti-D haemolytic disease of fetal and newborn in rhesus D negative primigravida.
Hassan MZ; Iberahim S; Abdul Rahman WSW; Zulkafli Z; Bahar R; Ramli M; Mohd Noor NH; Mustaffa R
Malays J Pathol; 2019 Apr; 41(1):55-58. PubMed ID: 31025639
[TBL] [Abstract][Full Text] [Related]
19. Identification of red blood cell antibodies in maternal breast milk implicated in prolonged hemolytic disease of the fetus and newborn.
Leonard A; Hittson Boal L; Pary P; Mo YD; Jacquot C; Luban NL; Darbari DS; Webb J
Transfusion; 2019 Apr; 59(4):1183-1189. PubMed ID: 30720868
[TBL] [Abstract][Full Text] [Related]
20. Modulating IgG effector function by Fc glycan engineering.
Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
